(BHC) Bausch Health Companies - Overview
Exchange: NYSE •
Country: Canada •
Currency: USD •
Type: Common Stock •
ISIN: CA0717341071
Stock: Pharmaceuticals, Medical Devices, Eye Care, Dermatology, Aesthetics
Total Rating 26
Risk 53
Buy Signal -1.43
| Risk 5d forecast | |
|---|---|
| Volatility | 54.3% |
| Relative Tail Risk | -12.0% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.38 |
| Alpha | -52.93 |
| Character TTM | |
|---|---|
| Beta | 1.385 |
| Beta Downside | 1.533 |
| Drawdowns 3y | |
|---|---|
| Max DD | 59.28% |
| CAGR/Max DD | -0.23 |
EPS (Earnings per Share)
Revenue
Risks
Technicals:
choppy
Description: BHC Bausch Health Companies March 04, 2026
Bausch Health Companies Inc. (BHC) is a diversified pharmaceutical and medical device company.
Its product portfolio spans gastroenterology, hepatology, neurology, dermatology, generics, over-the-counter (OTC) products, aesthetic medical devices, and eye health.
The company operates through five segments: Salix (gastroenterology), International (aesthetic medical devices, branded and generic pharmaceuticals, OTC), Solta Medical (aesthetic medical devices), Diversified (neurology, dermatology, generics, dentistry), and Bausch + Lomb (vision care, surgical, pharmaceuticals).
The pharmaceutical sector is characterized by extensive research and development cycles and regulatory approval processes.
Understanding the specific revenue contributions of these segments can provide further insight into BHCs business model. ValueRay can help you explore these details.
Headlines to watch out for
- Salix gastroenterology product sales drive revenue growth
- Bausch + Lomb eye care product demand impacts performance
- Generic pharmaceutical competition pressures profit margins
- Regulatory approvals for new drugs influence future sales
- Foreign currency fluctuations affect international segment profitability
Piotroski VR‑10 (Strict, 0-10) 3.5
| Net Income: 155.3m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.04 > 0.02 and ΔFCF/TA -0.96 > 1.0 |
| NWC/Revenue: 19.14% < 20% (prev -10.16%; Δ 29.30% < -1%) |
| CFO/TA 0.05 > 3% & CFO 1.40b > Net Income 155.3m |
| Net Debt (19.88b) to EBITDA (2.96b): 6.71 < 3 |
| Current Ratio: 1.47 > 1.5 & < 3 |
| Outstanding Shares: last quarter (370.5m) vs 12m ago -0.39% < -2% |
| Gross Margin: 68.33% > 18% (prev 0.71%; Δ 6.76k% > 0.5%) |
| Asset Turnover: 39.02% > 50% (prev 36.29%; Δ 2.73% > 0%) |
| Interest Coverage Ratio: 1.15 > 6 (EBITDA TTM 2.96b / Interest Expense TTM 1.52b) |
Altman Z'' -0.30
| A: 0.07 (Total Current Assets 6.15b - Total Current Liabilities 4.17b) / Total Assets 26.32b |
| B: -0.37 (Retained Earnings -9.65b / Total Assets 26.32b) |
| C: 0.07 (EBIT TTM 1.75b / Avg Total Assets 26.42b) |
| D: -0.04 (Book Value of Equity -909.3m / Total Liabilities 25.94b) |
| Altman-Z'' Score: -0.30 = B |
Beneish M -2.99
| DSRI: 1.02 (Receivables 2.35b/2.14b, Revenue 10.31b/9.62b) |
| GMI: 1.04 (GM 68.33% / 71.10%) |
| AQI: 0.96 (AQ_t 0.69 / AQ_t-1 0.72) |
| SGI: 1.07 (Revenue 10.31b / 9.62b) |
| TATA: -0.05 (NI 155.3m - CFO 1.40b) / TA 26.32b) |
| Beneish M-Score: -2.99 (Cap -4..+1) = A |
What is the price of BHC shares?
As of March 17, 2026, the stock is trading at USD 4.96 with a total of 2,067,043 shares traded.
Over the past week, the price has changed by -7.29%, over one month by -17.20%, over three months by -28.22% and over the past year by -29.55%.
Over the past week, the price has changed by -7.29%, over one month by -17.20%, over three months by -28.22% and over the past year by -29.55%.
Is BHC a buy, sell or hold?
Bausch Health Companies has received a consensus analysts rating of 3.00.
Therefor, it is recommend to hold BHC.
- StrongBuy: 0
- Buy: 1
- Hold: 5
- Sell: 1
- StrongSell: 0
What are the forecasts/targets for the BHC price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 7.7 | 55.4% |
| Analysts Target Price | 7.7 | 55.4% |
BHC Fundamental Data Overview March 12, 2026
P/E Trailing = 12.8571
P/E Forward = 1.2279
P/S = 0.1953
P/B = 18.7773
P/EG = 0.011
Revenue TTM = 10.31b USD
EBIT TTM = 1.75b USD
EBITDA TTM = 2.96b USD
Long Term Debt = 20.59b USD (from longTermDebt, last quarter)
Short Term Debt = 296.5m USD (from shortTermDebt, last quarter)
Debt = 21.21b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 19.88b USD (from netDebt column, last quarter)
Enterprise Value = 21.90b USD (2.00b + Debt 21.21b - CCE 1.31b)
Interest Coverage Ratio = 1.15 (Ebit TTM 1.75b / Interest Expense TTM 1.52b)
EV/FCF = 22.05x (Enterprise Value 21.90b / FCF TTM 993.5m)
FCF Yield = 4.54% (FCF TTM 993.5m / Enterprise Value 21.90b)
FCF Margin = 9.64% (FCF TTM 993.5m / Revenue TTM 10.31b)
Net Margin = 1.51% (Net Income TTM 155.3m / Revenue TTM 10.31b)
Gross Margin = 68.33% ((Revenue TTM 10.31b - Cost of Revenue TTM 3.26b) / Revenue TTM)
Gross Margin QoQ = 63.02% (prev 72.03%)
Tobins Q-Ratio = 0.83 (Enterprise Value 21.90b / Total Assets 26.32b)
Interest Expense / Debt = 1.45% (Interest Expense 308.1m / Debt 21.21b)
Taxrate = 21.0% (US default 21%)
NOPAT = 1.38b (EBIT 1.75b * (1 - 21.00%))
Current Ratio = 1.47 (Total Current Assets 6.15b / Total Current Liabilities 4.17b)
Debt / Equity = -38.35 (negative equity) (Debt 21.21b / totalStockholderEquity, last quarter -553.0m)
Debt / EBITDA = 6.71 (Net Debt 19.88b / EBITDA 2.96b)
Debt / FCF = 20.01 (Net Debt 19.88b / FCF TTM 993.5m)
Total Stockholder Equity = -766.1m (last 4 quarters mean from totalStockholderEquity)
RoA = 0.59% (Net Income 155.3m / Total Assets 26.32b)
RoE = -20.27% (negative equity) (Net Income TTM 155.3m / Total Stockholder Equity -766.1m)
RoCE = 8.82% (EBIT 1.75b / Capital Employed (Equity -766.1m + L.T.Debt 20.59b))
RoIC = 6.74% (NOPAT 1.38b / Invested Capital 20.51b)
WACC = 2.00% (E(2.00b)/V(23.21b) * Re(11.02%) + D(21.21b)/V(23.21b) * Rd(1.45%) * (1-Tc(0.21)))
Discount Rate = 11.02% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 33.33 | Cagr: 0.72%
[DCF] Terminal Value 80.82% ; FCFF base≈1.10b ; Y1≈720.9m ; Y5≈328.9m
[DCF] Fair Price = N/A (negative equity: EV 10.48b - Net Debt 19.88b = -9.40b; debt exceeds intrinsic value)
EPS Correlation: -2.34 | EPS CAGR: 11.58% | SUE: -0.31 | # QB: 0
Revenue Correlation: 90.37 | Revenue CAGR: 11.02% | SUE: 2.64 | # QB: 2
EPS next Quarter (2026-06-30): EPS=1.00 | Chg7d=+0.001 | Chg30d=+0.035 | Revisions Net=+2 | Analysts=6
EPS current Year (2026-12-31): EPS=4.33 | Chg7d=+0.129 | Chg30d=+0.132 | Revisions Net=+0 | Growth EPS=+15.5% | Growth Revenue=+4.0%
EPS next Year (2027-12-31): EPS=3.88 | Chg7d=+0.106 | Chg30d=+0.379 | Revisions Net=+1 | Growth EPS=-10.3% | Growth Revenue=+0.1%
[Analyst] Revisions Ratio: +1.00 (2 Up / 0 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 3.2% (Discount Rate 11.0% - Earnings Yield 7.8%)
[Growth] Growth Spread = +1.6% (Analyst 4.8% - Implied 3.2%)
P/E Forward = 1.2279
P/S = 0.1953
P/B = 18.7773
P/EG = 0.011
Revenue TTM = 10.31b USD
EBIT TTM = 1.75b USD
EBITDA TTM = 2.96b USD
Long Term Debt = 20.59b USD (from longTermDebt, last quarter)
Short Term Debt = 296.5m USD (from shortTermDebt, last quarter)
Debt = 21.21b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 19.88b USD (from netDebt column, last quarter)
Enterprise Value = 21.90b USD (2.00b + Debt 21.21b - CCE 1.31b)
Interest Coverage Ratio = 1.15 (Ebit TTM 1.75b / Interest Expense TTM 1.52b)
EV/FCF = 22.05x (Enterprise Value 21.90b / FCF TTM 993.5m)
FCF Yield = 4.54% (FCF TTM 993.5m / Enterprise Value 21.90b)
FCF Margin = 9.64% (FCF TTM 993.5m / Revenue TTM 10.31b)
Net Margin = 1.51% (Net Income TTM 155.3m / Revenue TTM 10.31b)
Gross Margin = 68.33% ((Revenue TTM 10.31b - Cost of Revenue TTM 3.26b) / Revenue TTM)
Gross Margin QoQ = 63.02% (prev 72.03%)
Tobins Q-Ratio = 0.83 (Enterprise Value 21.90b / Total Assets 26.32b)
Interest Expense / Debt = 1.45% (Interest Expense 308.1m / Debt 21.21b)
Taxrate = 21.0% (US default 21%)
NOPAT = 1.38b (EBIT 1.75b * (1 - 21.00%))
Current Ratio = 1.47 (Total Current Assets 6.15b / Total Current Liabilities 4.17b)
Debt / Equity = -38.35 (negative equity) (Debt 21.21b / totalStockholderEquity, last quarter -553.0m)
Debt / EBITDA = 6.71 (Net Debt 19.88b / EBITDA 2.96b)
Debt / FCF = 20.01 (Net Debt 19.88b / FCF TTM 993.5m)
Total Stockholder Equity = -766.1m (last 4 quarters mean from totalStockholderEquity)
RoA = 0.59% (Net Income 155.3m / Total Assets 26.32b)
RoE = -20.27% (negative equity) (Net Income TTM 155.3m / Total Stockholder Equity -766.1m)
RoCE = 8.82% (EBIT 1.75b / Capital Employed (Equity -766.1m + L.T.Debt 20.59b))
RoIC = 6.74% (NOPAT 1.38b / Invested Capital 20.51b)
WACC = 2.00% (E(2.00b)/V(23.21b) * Re(11.02%) + D(21.21b)/V(23.21b) * Rd(1.45%) * (1-Tc(0.21)))
Discount Rate = 11.02% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 33.33 | Cagr: 0.72%
[DCF] Terminal Value 80.82% ; FCFF base≈1.10b ; Y1≈720.9m ; Y5≈328.9m
[DCF] Fair Price = N/A (negative equity: EV 10.48b - Net Debt 19.88b = -9.40b; debt exceeds intrinsic value)
EPS Correlation: -2.34 | EPS CAGR: 11.58% | SUE: -0.31 | # QB: 0
Revenue Correlation: 90.37 | Revenue CAGR: 11.02% | SUE: 2.64 | # QB: 2
EPS next Quarter (2026-06-30): EPS=1.00 | Chg7d=+0.001 | Chg30d=+0.035 | Revisions Net=+2 | Analysts=6
EPS current Year (2026-12-31): EPS=4.33 | Chg7d=+0.129 | Chg30d=+0.132 | Revisions Net=+0 | Growth EPS=+15.5% | Growth Revenue=+4.0%
EPS next Year (2027-12-31): EPS=3.88 | Chg7d=+0.106 | Chg30d=+0.379 | Revisions Net=+1 | Growth EPS=-10.3% | Growth Revenue=+0.1%
[Analyst] Revisions Ratio: +1.00 (2 Up / 0 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 3.2% (Discount Rate 11.0% - Earnings Yield 7.8%)
[Growth] Growth Spread = +1.6% (Analyst 4.8% - Implied 3.2%)